Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CIMYM formally notified Oncoscience that it no longer intends to submit application to the London Court of International Arbitration
Subscribe to our email newsletter
YM BioSciences has reported that it’s subsidiary CIMYM BioSciences, and Oncoscience have resolved the issues between the companies. CIMYM has formally notified Oncoscience that it no longer intends to submit its application to the London Court of International Arbitration, for resolution of the matters previously in dispute.
David Allan, Chairman and CEO, YM BioSciences, said: We are pleased that CIMYM BioSciences and Oncoscience have resolved their differences amicably at a minimal cost to either party and that each are committed to cooperate fully in moving nimotuzumab forward clinically with all due deliberate speed.
The late-stage European clinical program Oncoscience is undertaking contributes significantly to the broad program being advanced by the network of cooperative relationships dedicated to the development of this important cancer drug globally,” he added.